Cytokines and chemokines in SARS-CoV-2 infections—therapeutic strategies targeting cytokine storm
A Pum, M Ennemoser, T Adage, AJ Kungl - Biomolecules, 2021 - mdpi.com
The recently identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
virus, the cause of coronavirus disease (COVID-19) and the associated ongoing pandemic …
virus, the cause of coronavirus disease (COVID-19) and the associated ongoing pandemic …
[HTML][HTML] Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis
CW Nugroho, SD Suryantoro, Y Yuliasih… - …, 2021 - ncbi.nlm.nih.gov
Background: Several studies have revealed the potential use of tocilizumab in treating
COVID-19 since no therapy has yet been approved for COVID-19 pneumonia. Tocilizumab …
COVID-19 since no therapy has yet been approved for COVID-19 pneumonia. Tocilizumab …
Systematic review and meta-analysis of tocilizumab therapy versus standard of care in over 15,000 COVID-19 pneumonia patients during the first eight months of the …
Background. Tocilizumab is an anti-IL-6 therapy widely adopted in the management of the
so-called “cytokine storm” related to SARS-CoV-2 virus infection, but its effectiveness, use in …
so-called “cytokine storm” related to SARS-CoV-2 virus infection, but its effectiveness, use in …
Evaluation of current therapies for COVID-19 treatment
A Sethi, H Bach - Microorganisms, 2020 - mdpi.com
The virus SARS-CoV-2, the etiological agent of COVID-19, is responsible for more than
400,000 deaths worldwide as of 10 June 2020. As a result of its recent appearance …
400,000 deaths worldwide as of 10 June 2020. As a result of its recent appearance …
Tocilizumab effectiveness in mechanically ventilated COVID-19 patients (T-MVC-19 Study): a multicenter real-world evidence
YA Mohzari, A Alamer, M Alattas… - Expert Review of Anti …, 2022 - Taylor & Francis
Background This study aimed to evaluate the effectiveness of tocilizumab in mechanically
ventilated patients with coronavirus disease 2019 (COVID-19). Research design and …
ventilated patients with coronavirus disease 2019 (COVID-19). Research design and …
Current drugs with potential for coronavirus disease 2019 therapy: a literature review
S Alihosseini, HE Leylabadlo, M Parsaei… - … and Research in …, 2022 - journals.lww.com
Abstract Coronavirus disease 2019 (COVID-19) was declared as a pandemic by the WHO
on 2020 a novel disease with no confirmed and precise therapeutic agent …
on 2020 a novel disease with no confirmed and precise therapeutic agent …
[PDF][PDF] Cytokines and Chemokines in SARS-CoV-2 Infections—Therapeutic Strategies Targeting Cytokine Storm. Biomolecules 2021, 11, 91
A Pum, M Ennemoser, T Adage, AJ Kungl - 2021 - pdfs.semanticscholar.org
The recently identified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
virus, the cause of coronavirus disease (COVID-19) and the associated ongoing pandemic …
virus, the cause of coronavirus disease (COVID-19) and the associated ongoing pandemic …
[PDF][PDF] Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis [version 1; peer review
Background: Several studies have revealed the potential use of tocilizumab in treating
COVID-19 since no therapy has yet been approved for COVID-19 pneumonia. Tocilizumab …
COVID-19 since no therapy has yet been approved for COVID-19 pneumonia. Tocilizumab …